Back to top
more

Immunocore (IMCR)

(Delayed Data from NSDQ)

$41.68 USD

41.68
778,754

-1.01 (-2.37%)

Updated Jun 7, 2024 04:00 PM ET

After-Market: $41.66 -0.02 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

bluebird bio (BLUE) Rides High on Its Gene Therapy Approvals

by Zacks Equity Research

bluebird's (BLUE) recent FDA approvals for its gene therapies, namely beta-cel for beta-thalassemia and eli-cel for cerebral adrenoleukodystrophy, will likely drive the top line.

Teva Pharmaceutical (TEVA) Names Richard Francis as New CEO

by Zacks Equity Research

Teva Pharmaceutical (TEVA) appoints Richard Francis as the company's new president and chief executive officer, effective from Jan 1, 2023.

Zacks.com featured highlights include Immunocore Holdings, Old Second Bancorp, EDAP TMS, Barrett Business Services and MainStreet Bancshares

by Zacks Equity Research

Immunocore Holdings, Old Second Bancorp, EDAP TMS, Barrett Business Services and MainStreet Bancshares are part of the Zacks Screen of the Week article.

Nalak Das headshot

5 Stocks With Recent Price Strength to Maximize Your Gains

by Nalak Das

Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are IMCR, EDAP, BBSI, OSBC and MNSB.

Intra-Cellular's (ITCI) Caplyta Aids Growth, Overdependence a Woe

by Zacks Equity Research

Intra-Cellular Therapeutics (ITCI) currently has only one marketed product in its portfolio, Caplyta, approved for schizophrenia and bipolar disorders. The company is evaluating the candidate in several other indications.

Monopar Therapeutics (MNPR) Up On Soft Tissue Sarcoma Study Data

by Zacks Equity Research

Monopar Therapeutics (MNPR) surges after it reports data from its ongoing phase Ib dose escalation study evaluating camsirubicin for treating soft-tissue sarcoma.

Inhibrx (INBX) Down on Updated Data From Bone Cancer Study

by Zacks Equity Research

Inhibrx (INBX) shares fall after it reports safety and efficacy data from phase I cohorts of a study evaluating its lead candidate INBRX-109 for chondrosarcoma.

Editas (EDIT) Pauses Eye Disease Study on EDIT-101, Stock Down

by Zacks Equity Research

Editas (EDIT) pauses enrollment in the phase I/II BRILLIANCE study evaluating EDIT-101 for treating blindness due to Leber congenital amaurosis 10. Stock falls.

Are Medical Stocks Lagging Immunocore (IMCR) This Year?

by Zacks Equity Research

Here is how Immunocore Holdings PLC Sponsored ADR (IMCR) and Medpace (MEDP) have performed compared to their sector so far this year.

Immunovant (IMVT) Rises More Than 150% in 3 Months: Here's How

by Zacks Equity Research

Immunovant (IMVT) is making good progress with its lead pipeline candidate, batoclimab, which is being developed for treating myasthenia gravis, thyroid eye disease and other autoimmune diseases.

Arcutis (ARQT) Up on Top-Line Data From Atopic Dermatitis Study

by Zacks Equity Research

Arcutis Biotherapeutics (ARQT) reports positive top-line data from a phase III study of its lead candidate, roflumilast cream 0.15%, for treating atopic dermatitis.

What Makes Immunocore Holdings PLC Sponsored ADR (IMCR) a Good Fit for "Trend Investing"

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, Immunocore Holdings PLC Sponsored ADR (IMCR) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Why Immunocore (IMCR) Might Surprise This Earnings Season

by Zacks Equity Research

Immunocore (IMCR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Best Momentum Stocks to Buy for November 3rd

by Zacks Equity Research

PDS, IMCR and USER made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 3, 2022.

New Strong Buy Stocks for November 3rd

by Zacks Equity Research

ALX, PDS, IMCR, PXS and CFR have been added to the Zacks Rank #1 (Strong Buy) List on November 3, 2022.

Can Humana (HUM) Sustain Its Earnings Beat Streak in Q3?

by Zacks Equity Research

Humana's (HUM) Q3 results are expected to reflect growing premiums, attributable to its Medicare Advantage and Medicaid businesses. However, elevated marketing costs might have strained its margins.

Wall Street Analysts Predict a 30% Upside in Immunocore Holdings PLC Sponsored ADR (IMCR): Here's What You Should Know

by Zacks Equity Research

The mean of analysts' price targets for Immunocore Holdings PLC Sponsored ADR (IMCR) points to a 29.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Sesen Bio (SESN) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Sesen Bio's (SESN) third-quarter earnings are likely to reflect the cost savings from the company's restructuring plans.

AVEO Oncology (AVEO) to Report Q3 Earnings: Is a Beat in Store?

by Zacks Equity Research

AVEO Oncology's (AVEO) third-quarter earnings is expected to reflect strong Fotivda sales. The company is likely to beat the Zacks Consensus Estimate.

Mind Medicine (MNMD) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

Mind Medicine MindMed (MNMD) is expected to provide an update on its pipeline candidates in its third-quarter earnings.

Strength Seen in Immunocore Holdings PLC Sponsored ADR (IMCR): Can Its 10.2% Jump Turn into More Strength?

by Zacks Equity Research

Immunocore Holdings PLC Sponsored ADR (IMCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

VBI Vaccine (VBIV) Inks Deal With Agenus for Brain Cancer Study

by Zacks Equity Research

VBI Vaccines (VBIV) enters into a partnership with Agenus to conduct a study evaluating the former's VBI-1901 in combination with the latter's balstilimab for primary glioblastoma.

DICE Therapeutics (DICE) Up on Top-Line Data From Psoriasis Study

by Zacks Equity Research

DICE Therapeutics (DICE) reports positive top-line data from a phase I study, evaluating its lead candidate DC-806 for treating psoriasis. Stock up.

Albireo (ALBO) Up on Results From Alagille Syndrome Study

by Zacks Equity Research

Albireo Pharma (ALBO) reports positive top-line data from a late-stage study evaluating Bylvay in Alagille syndrome. The study meets the primary and key secondary endpoint Stock up.

scPharmaceuticals (SCPH) Plunges Despite Furoscix's FDA Approval

by Zacks Equity Research

scPharmaceuticals (SCPH) receives FDA approval for its proprietary heart failure therapy. It also reported a debt refinancing agreement to help with the drug launch.